N-t-butyl-N - t-butoxycarbonylhydrazine | 126632-91-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-t-butyl-N - t-butoxycarbonylhydrazine
• 英文别名: tert-butyl N-amino-N-tert-butylcarbamate
• CAS: 126632-91-5
• 化学式: C₉H₂₀N₂O₂
• 分子量: 188.27
• InChiKey: RHDCEWMSJPTOKB-UHFFFAOYSA-N

物化性质

• 沸点：
  235.4±23.0 °C(Predicted)
• 密度：
  0.982±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  二碳酸二叔丁酯 、 叔丁基肼盐酸盐 以 1,4-二氧六环 、 sodium hydroxide 为溶剂， 生成 N-t-butyl-N - t-butoxycarbonylhydrazine
  参考文献：
  名称：

  Six-membered heterocyclic derivatives of N'substituted-N,N'-diacylhydrazines

  摘要：

  公开号：

  EP0253468B1

文献信息

• HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR
  申请人：North China Pharmaceutical Company., Ltd.

  公开号：EP3147283A1

  公开（公告）日：2017-03-29

  Provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X is selected from a 3-9 membered carbon ring or its phenyl ring, and a 4-10 membered heterocyclic ring or its benzo ring; Y and Z are independently selected from 4-9 membered saturated heterocyclic rings respectively; RI-3 are independently selected from H, F, Cl, Br, I, CN, OH, SH,NH2, CHO, COOH respectively, or selected from C1-10 alkyls or heteroalkyls optionally substituted by R01, C3-10 alkyls ring hydrocarbon groups or heterocyclic hydrocarbon groups, C1-10 alkyls or heteroalkyls substituted by C3-10 ring hydrocarbon groups or heterocyclic hydrocarbon group. The compound can be used as an anticoagulant for treating and preventing thrombotic disorders, and can meet the real needs of selectivity and a potent inhibitor for coagulation Xa.

  提供的是式(I)化合物或其药学上可接受的盐，其中X选自3-9个成员的碳环或其苯基环，以及4-10个成员的杂环或其苯环；Y和Z分别独立地选自4-9个成员的饱和杂环；RI-3 分别独立地选自 H、F、Cl、Br、I、CN、OH、SH、NH2、CHO、COOH，或选自任选被 R01 取代的 C1-10 烷基或杂烷基、C3-10 烷基环烃基团或杂环烃基团、被 C3-10 环烃基团或杂环烃基团取代的 C1-10 烷基或杂烷基。该化合物可用作治疗和预防血栓性疾病的抗凝剂，能满足对凝血 Xa 的选择性和强效抑制剂的实际需要。
• HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR XA INHIBITOR
  申请人：North China Pharmaceutical Company., Ltd.

  公开号：EP3147283B1

  公开（公告）日：2022-08-17
• FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2516434A1

  公开（公告）日：2012-10-31
• [EN] FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS<br/>[FR] PYRROLIDINONES ACCOLÉS EN TANT D'INHIBITEURS DE SYK
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2011079051A1

  公开（公告）日：2011-06-30

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
• Six-membered heterocyclic derivatives of N'substituted-N,N'-diacylhydrazines
  申请人：ROHM AND HAAS COMPANY

  公开号：EP0253468B1

  公开（公告）日：1991-11-06